A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Leigh Syndrome

Interventions

DRUG

TTI-0102: cysteamine-pantetheine disulfide

TTI-0102: cysteamine-pantetheine disulfide, powder for dissolution in water for oral administration

DRUG

D-Mannitol

All Listed Sponsors

lead

Thiogenesis Therapeutics, Inc.

INDUSTRY